Kairos Pharma Ltd. (NYSE: KAPA)’s Post

🌍 Kexing Biopharm Partners with Qingfeng Pharma to Bring Olaparib Tablets to Global Markets!  💪 Olaparib Tablets, as a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, were initially indicated for BRCA-mutated advanced ovarian cancer, and subsequently expanded to ovarian cancer, breast cancer, pancreatic cancer, prostate cancer and other malignancies. It is a first-line therapeutic agent for breast cancer and a first-line maintenance therapy for ovarian cancer recommended by the NCCN clinical guidelines. 🎗️ #Breast and ovarian cancers are prevalent worldwide, with a booming market expected to surpass USD 50 billion. The addition of Olaparib underscores our dedication to providing comprehensive solutions for #breastcancer globally. #GlobalHealth #CancerTreatment #Innovation #KexingBiopharm #Olaparib

(Celecoxib + tucidinostat) by Great Novel Therapeutics Biotech & Medicals for Metastatic Colorectal Cancer. (Celecoxib + tucidinostat) is under clinical development by Great Novel Therapeutics Biotech & Medicals and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData Plc 's report assesses how (Celecoxib + tucidinostat)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare... Check out the full story 👉 https://zurl.co/wV3s (PHARMAC) #biotech #genetics

𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐓𝐨 https://lnkd.in/euN7Z8i8 𝐠𝐞𝐭 𝐰𝐞𝐥𝐥-𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 The Mexico Antibody Drug Conjugates (ADC) Market is paving the way for groundbreaking advancements in oncology. Combining the precision of antibodies with the potency of cytotoxic drugs, ADCs are redefining cancer treatment by targeting cancer cells while sparing healthy tissue. With increasing investments in biotech R&D and growing adoption of personalized medicine, Mexico is emerging as a key player in the ADC landscape. 🚀 The future of oncology is here—focused, effective, and life-changing. To Get more:https://lnkd.in/dCyCfKzM #AntibodyDrugConjugates #OncologyInnovation #BiotechMexico #TargetedTherapies #PharmaTrends"

𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗺𝗲𝗱𝗶𝗮𝘁𝗼𝗿 𝗼𝗳 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝗱! Lung cancer is the primary cause of cancer-related deaths globally, accounting for one-third of all cancer deaths. The EGF receptor plays a crucial role in driving lung cancer, but targeted therapies often result in drug resistance. A recent study that used our TRC research chemicals (TRC-M325750) identified a critical mediator of lung cancer drug resistance. Read the findings in the journal Oncogene: https://okt.to/TZj2rO Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/sdm9ef #LungCancer #oncology #oncologyresearch #ResearchChemicals

🏆 €1.36M awarded to AtG Therapeutics by Eurostars! Their project, 'Novel Intracellular Approach to Combat Renal Cancer', expedites the development of a first-in-class intracellular Tumour Adaptation-1 (TA-1) inhibitor for treatment of drug-resistant advanced renal cell carcinoma (RCC). With their TA-1 inhibitor, AtG Therapeutics address the high unmet need for effective drugs to overcome tumour resistance in late-stage RCC patients. “Our objective is to enhance the survival rates and quality of life of patients with advanced renal cancer.” Gabriela Jiménez Valerio, PhD., Co-Founder & COO, commented. We are proud of this result and pleased to share Gabriela's positive feedback of the collaboration: “Our experience with Catalyze was outstanding, and their support was instrumental in the success of our Eurostars application." 🔗 Read more here: https://lnkd.in/gvzTrhrS #AtGTherapeutics #Eurostars #renalcellcarcinoma #Catalyze

ATR inhibition is a promising strategy for cancer therapeutics. At Aprea, we are developing ATRN-119, a differentiated macrocyclic and highly selective, potent, oral ATR inhibitor with antitumor activity. Preliminary results of our ongoing first-in-human study of ATRN-119 were presented recently at the ENA conference. Learn more about Aprea’s pipeline: https://lnkd.in/gtx7gTTK #PrecisionOncology #Data #ClinicalTrials 

Bispecific antibodies have become increasingly of interest by enabling new therapeutic applications for a variety of indications, including cancer. In this webinar, Dr. Sai Wang, protein senior scientist at GenScript Biotech Singapore, will discuss the advantages of bispecific antibodies (bsAbs), their mechanism of action (MOA), and the development history of bsAb platform. #bispecificantibodies #therapeutics #cancer #bsAbs #webinar

Making Cancer Treatments Work Again. At Kairos Pharma, we're tackling cancer drug resistance head-on. Our groundbreaking approach targets CD105, a protein that signals cancer cells to override therapeutic effects. By developing antibodies that reverse this resistance, we're working to make existing cancer treatments effective again. As our CEO Dr. John Yu says, "We don't need to compete with big pharma - we make their drugs work again when patients develop resistance." NYSE: KAPA #BiotechInnovation #CancerResearch #DrugDiscovery #PersonalizedMedicine

Antibody-drug conjugates (ADCs) have emerged as a revolutionary approach to cancer treatment, enabling the targeted delivery of cytotoxic drugs to cancer cells while minimizing systemic toxicity. The global ADC market is witnessing remarkable growth, fueled by advancements in linker technologies, extensive research and development efforts, and the rising global incidence of cancer. In Taiwan, several companies are actively engaged in the development and manufacturing of ADCs, contributing significantly to the global oncology landscape. Download our FREE eBook: 𝐀 𝐋𝐨𝐨𝐤 𝐚𝐭 𝐓𝐚𝐢𝐰𝐚𝐧'𝐬 𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐀𝐃𝐂 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐚𝐧𝐝 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 for more insights. DOWNLOAD HERE: https://lnkd.in/gDEb2HSH #imagineyourimpact #antibodydrugconjugates #ADC2025

Nature: Bispecific antibodies, against the transferrin receptor (highly expressed in cancer) and cancer membrane proteins, trigger co-internalisation and co-degradation. In this study they were made to target EGFR, PD-L1, and CD20, and killed drug-resistant cancer lines. They represent a promising new family of bifunctional antibodies for precise manipulation of membrane proteins and targeted cancer therapy. https://lnkd.in/e4r9gUbh #medicine #research #healthcare #health #drugdevelopment #pharmaceutical #oncology #cancer #cancerresearch #innovation #technology